Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Matthew Holt
On December 11, 2016, Matthew Holt notified Bellerophon Therapeutics, Inc. (the “Company”) that he will resign as a director of the Company effective immediately. Mr. Holt’s decision was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Holt served as a director of the Company since February 2014.
Election of Fabian Tenenbaum
Effective December 11, 2016, the Board of Directors of the Company elected Fabian Tenenbaum, the Company’s current Chief Executive Officer, as a director.
About Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Recent Trading Information
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) closed its last trading session down -0.015 at 0.500 with 2,773,319 shares trading hands.
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Recent Trading Information
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) closed its last trading session down -0.015 at 0.500 with 2,773,319 shares trading hands.
